X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
2.850
-0.200 (-6.56%)
Jun 13, 2025, 2:26 PM - Market open
X4 Pharmaceuticals Stock Forecast
XFOR's stock price has decreased by -91.38% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for X4 Pharmaceuticals stock ranges from a low of $7.00 to a high of $120. The average analyst price target of $72.33 forecasts a 2,437.89% increase in the stock price over the next year.
Price Target: $72.33 (+2,437.89%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 2, 2025.
Analyst Ratings
The average analyst rating for X4 Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $1.5 → $7 | Strong Buy | Maintains | $1.5 → $7 | +145.61% | May 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +1,478.95% | Mar 27, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $90 | Buy | Reiterates | $90 | +3,057.89% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +1,478.95% | Feb 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +1,478.95% | Jan 14, 2025 |
Financial Forecast
Revenue This Year
30.85M
from 2.56M
Increased by 1,106.53%
Revenue Next Year
25.84M
from 30.85M
Decreased by -16.26%
EPS This Year
-19.92
from -5.59
EPS Next Year
-8.94
from -19.92
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 38.3M | 35.9M | 332.5M | ||
| Avg | 30.9M | 25.8M | 114.9M | ||
| Low | 9.6M | 16.1M | 35.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,398.8% | 16.4% | 1,187.2% | ||
| Avg | 1,106.5% | -16.3% | 344.9% | ||
| Low | 275.6% | -47.9% | 35.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.28 | -3.44 | -2.52 | ||
| Avg | -19.92 | -8.94 | -3.01 | ||
| Low | -59.78 | -17.16 | -3.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.